286 related articles for article (PubMed ID: 27439433)
1. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
Doyle MA; Singer J; Lee T; Muir M; Cooper C
Trials; 2016 Jul; 17(1):331. PubMed ID: 27439433
[TBL] [Abstract][Full Text] [Related]
2. [ANRS-fibrovic and homavic: role of non invasive markers of liver fibrosis and insulin resistance during antiviral treatment in HIV-HCV co-infected patients from ANRS HC 02 RIVABIC trial].
Halfon P; Pénaranda G; Cacoub P
Gastroenterol Clin Biol; 2009 Mar; 33 Suppl 2():S113-7. PubMed ID: 19375039
[TBL] [Abstract][Full Text] [Related]
3. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
Halfon P; Pénaranda G; Carrat F; Bedossa P; Bourlière M; Ouzan D; Renou C; Tran A; Rosenthal E; Wartelle C; Delasalle P; Cacoub P
Aliment Pharmacol Ther; 2009 Jul; 30(1):61-70. PubMed ID: 19292832
[TBL] [Abstract][Full Text] [Related]
4. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
5. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
6. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
7. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
[TBL] [Abstract][Full Text] [Related]
9. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
[TBL] [Abstract][Full Text] [Related]
10. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
11. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
12. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.
Chapplain JM; Bellissant E; Guyader D; Molina JM; Poizot-Martin I; Perré P; Pialoux G; Turlin B; Mouchel C; Renault A; Michelet C;
J Infect; 2013 Oct; 67(4):313-21. PubMed ID: 23800784
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
[TBL] [Abstract][Full Text] [Related]
15. More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.
Ding Y; Duan S; Ye R; Yang Y; Yao S; Wang J; Cao D; Liu X; Lu L; Jia M; Wu Z; He N
J Viral Hepat; 2017 May; 24(5):412-420. PubMed ID: 27925409
[TBL] [Abstract][Full Text] [Related]
16. INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES.
Andrade VG; Yamashiro FDS; Oliveira CV; Moreira A; Winckler FC; Silva GF
Arq Gastroenterol; 2018; 55(3):274-278. PubMed ID: 30540091
[TBL] [Abstract][Full Text] [Related]
17. Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients.
Nilsson J; Weiland O
Scand J Infect Dis; 2010 Jul; 42(6-7):533-9. PubMed ID: 20214543
[TBL] [Abstract][Full Text] [Related]
18. Management of hepatitis C in HIV infected and other immunocompromised individuals.
Seth AK
Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients.
Merchante N; Rivero A; de Los Santos-Gil I; Merino D; Márquez M; López-Ruz MA; Rodríguez-Baño J; Del Valle J; Camacho A; Sanz-Sanz J; Macías J; Pérez-Camacho I; Gómez-Mateos J; Moro A; Pineda JA
Gut; 2009 Dec; 58(12):1654-60. PubMed ID: 19625279
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
